Pure Global AI
NCT05770895Recruiting

Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)
Gilead SciencesPhase 1ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Chronic Hepatitis B
Drug/Device/Intervention
GS-2829
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Gilead Sciences
Location
Auckland, New Zealand
Timeline & enrollment
Phase
Phase 1
Start date
Apr 03, 2023
End date
Nov 01, 2024
Enrollment
70 participants
Primary outcome

Percentage of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs),Percentage of Participants With Treatment-emergent Laboratory Abnormalities

Summary

The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy
 participants and participants with CHB.

ICD-10 classifications
Acute hepatitis BChronic viral hepatitis B without delta-agentAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agent : other and unspecified phaseChronic viral hepatitis B without delta-agent : immune-tolerant phase
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05770895
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05770895 through Pure Global AI's free database. This Phase 1 trial is sponsored by Gilead Sciences and is currently Recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 70 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.